PMID- 22659586
OWN - NLM
STAT- MEDLINE
DCOM- 20130523
LR  - 20120723
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 689
IP  - 1-3
DP  - 2012 Aug 15
TI  - Erythropoietin attenuates cardiopulmonary bypass-induced renal inflammatory 
      injury by inhibiting nuclear factor-kappaB p65 expression.
PG  - 154-9
LID - 10.1016/j.ejphar.2012.05.027 [doi]
AB  - Acute renal injury is one of the most frequent complications after 
      cardiopulmonary bypass (CPB). This study was designed to evaluate the potential 
      protective effect of erythropoietin (EPO) on CPB-induced renal injury in a rat 
      model. Male Sprague-Dawley rats were randomly divided into three groups, 
      sham-operated group (sham), control CPB group (control), erythropoietin CPB group 
      (EPO). Blood samples were collected at the beginning, at the end of CPB, and at 
      0.5, 1, 2 and 24 h post-operation, and the kidneys were harvested 24 h 
      postoperatively and observed by optical microscopy. Levels of serum creatinine 
      (Cr) and blood urea nitrogen (BUN) were assayed. Tumor necrosis factor-alpha (TNF-alpha), 
      interleukin-1beta (IL-1beta) and interleukin-6(IL-6) levels in the renal tissues were 
      evaluated by the method of enzyme linked immunosorbent assay (ELISA). Protein and 
      mRNA levels of nuclear factor kappa B p65 (NF-kappaB p65), intercellular adhesion 
      molecule-1 (ICAM-1) were also determined using western blot and real-time PCR 
      respectively. Serum Cr and BUN levels as well as TNF-alpha, IL-1beta and IL-6 levels in 
      renal tissues in control group were significantly higher than those in the sham 
      group. However, the levels of above biomarkers were markedly decreased in EPO 
      group when comparing with control group. Furthermore, NF-kappaB p65, ICAM-1 protein 
      and mRNA expression were significantly down-regulated in EPO group comparing with 
      control group. In addition, microscopic examinations revealed that histological 
      injury was alleviated when treated with EPO. The results indicated that EPO 
      potently protected against CPB-induced acute renal injury and inhibited 
      expression of NF-kappaB p65 and inflammatory response.
CI  - Copyright (c) 2012 Elsevier B.V. All rights reserved.
FAU - Wang, Gaoming
AU  - Wang G
AD  - Department of Cardiothoracic Surgery, Jinling Hospital, Clinical Medicine School 
      of Nanjing University, 305 East Zhongshan Road, Nanjing 210002, China.
FAU - Huang, Hairong
AU  - Huang H
FAU - Wu, Haiwei
AU  - Wu H
FAU - Wu, Chen
AU  - Wu C
FAU - Xu, Yanhui
AU  - Xu Y
FAU - Wang, Lian
AU  - Wang L
FAU - Liu, Xiaolong
AU  - Liu X
FAU - Wang, Changtian
AU  - Wang C
FAU - Shen, Yi
AU  - Shen Y
FAU - Li, Demin
AU  - Li D
FAU - Jing, Hua
AU  - Jing H
LA  - eng
PT  - Journal Article
DEP - 20120530
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Inflammation Mediators)
RN  - 0 (Transcription Factor RelA)
RN  - 11096-26-7 (Erythropoietin)
SB  - IM
MH  - Acute Kidney Injury/etiology/pathology/*prevention & control
MH  - Animals
MH  - Cardiopulmonary Bypass/*adverse effects
MH  - Erythropoietin/*physiology/therapeutic use
MH  - *Gene Expression Regulation
MH  - Inflammation Mediators/antagonists & inhibitors/metabolism
MH  - Male
MH  - Postoperative Complications/etiology/pathology/prevention & control
MH  - Random Allocation
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Transcription Factor RelA/*antagonists & inhibitors/*biosynthesis/genetics
EDAT- 2012/06/05 06:00
MHDA- 2013/05/25 06:00
CRDT- 2012/06/05 06:00
PHST- 2011/12/06 00:00 [received]
PHST- 2012/05/09 00:00 [revised]
PHST- 2012/05/16 00:00 [accepted]
PHST- 2012/06/05 06:00 [entrez]
PHST- 2012/06/05 06:00 [pubmed]
PHST- 2013/05/25 06:00 [medline]
AID - S0014-2999(12)00470-0 [pii]
AID - 10.1016/j.ejphar.2012.05.027 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2012 Aug 15;689(1-3):154-9. doi: 10.1016/j.ejphar.2012.05.027. 
      Epub 2012 May 30.